Audrey Hennequin
About
Audrey Hennequin is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery.
According to data from OpenAlex, Audrey Hennequin has authored 34 papers receiving a total of 561 indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Oncology, 14 papers in Pulmonary and Respiratory Medicine and 7 papers in Surgery. Recurrent topics in Audrey Hennequin's work include Colorectal Cancer Treatments and Studies (11 papers), Cancer Treatment and Pharmacology (10 papers) and Advanced Breast Cancer Therapies (8 papers). Audrey Hennequin is often cited by papers focused on Colorectal Cancer Treatments and Studies (11 papers), Cancer Treatment and Pharmacology (10 papers) and Advanced Breast Cancer Therapies (8 papers). Audrey Hennequin collaborates with scholars based in France, Spain and United Kingdom. Audrey Hennequin's co-authors include François Ghiringhelli, Valentin Dérangère, Sylvain Ladoire, Laurent Arnould, Julie Vincent, Romain Boidot, Aurélie Bertaut, Lionel Apétoh, David Orry and Françoise Beltjens and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and Breast Cancer Research.
In The Last Decade
Audrey Hennequin
31 papers receiving 556 citations
Peers
Audrey Hennequin
Andy Karabajakian France
R. Houston Thompson United Kingdom
Giulia Mazzaschi Italy
Virginia Palomar Coloma France
Petros Fessas United Kingdom
Éléonore De Guillebon France
Fanrong Zhang China
Casilda Llácer Spain
Muhammad Zubair Afzal United States
Rachel Marty Pyke United States
Citations per year, relative to Audrey Hennequin Audrey Hennequin (= 1×)
peers
Andy Karabajakian
Countries citing papers authored by Audrey Hennequin
Since
Specialization
Citations
This map shows the geographic impact of Audrey Hennequin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Audrey Hennequin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Audrey Hennequin more than expected).
Fields of papers citing papers by Audrey Hennequin
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Audrey Hennequin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Audrey Hennequin. The network helps show where Audrey Hennequin may publish in the future.
Co-authorship network of co-authors of Audrey Hennequin
This figure shows the co-authorship network connecting the top 25 collaborators of Audrey Hennequin. A scholar is included among the top collaborators of Audrey Hennequin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Audrey Hennequin. Audrey Hennequin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Bertaut, Aurélie, Alice Hervieu, Sylvie Zanetta, et al.. (2025). FOLFIRINOX-3 plus bevacizumab (bFOLFIRINOX3) in chemo-refractory metastatic colorectal cancer: a multicenter phase II trial. Future Oncology. 21(6). 699–706.
2.
Ladoire, Sylvain, Loïck Galland, Isabelle Desmoulins, et al.. (2025). Prevalence, clinicopathologic features and long-term overall survival of early breast cancer patients eligible for adjuvant abemaciclib and/or ribociclib. npj Breast Cancer. 11(1). 10–10.
3.
Ladoire, Sylvain, Loïck Galland, Isabelle Desmoulins, et al.. (2024). Real-world prevalence, treatment and survival of “high risk” early breast cancer, with mandatory testing of gBRCA1/2 mutation according to the OlympiA trial inclusion criteria: Data from a population-based registry. The Breast. 78. 103789–103789.
4.
Ghiringhelli, François, Valérie Jooste, Sylvain Manfrédi, et al.. (2023). Biliary tract cancers have distinct epidemiological patterns and clinical characteristics according to tumour site. HPB. 25(6). 693–703.
5.
Arnould, Laurent, Françoise Beltjens, Didier Mayeur, et al.. (2023). Pathologic complete response and survival in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy. Breast Cancer. 30(6). 997–1007.
6.
Piquemal, David, Florian Noguier, Barbara Bournet, et al.. (2023). SO-8 Predictive values of blood-based RNA signature for the FOLFIRINOX/FOLFOX response in advanced pancreatic cancer. Annals of Oncology. 34. S164–S165.
7.
Desmoulins, Isabelle, Didier Mayeur, Courèche Kaderbhaï, et al.. (2023). Taxane rechallenge during metastatic disease in HER-2 negative breast cancer patients: Clinical activity, tolerance and survival results. The Breast. 68. 149–156.
8.
Galland, Loïck, Isabelle Desmoulins, Didier Mayeur, et al.. (2023). Clinical Utility of Genomic Tests Evaluating Homologous Recombination Repair Deficiency (HRD) for Treatment Decisions in Early and Metastatic Breast Cancer. Cancers. 15(4). 1299–1299.
9.
Galland, Loïck, Elise Ballot, Romain Boidot, et al.. (2022). Efficacy of platinum-based chemotherapy in metastatic breast cancer and HRD biomarkers: utility of exome sequencing. npj Breast Cancer. 8(1). 28–28.
10.
Tourneau, C. Le, Heinrich Becker, Rainer Claus, et al.. (2022). Two phase I studies of BI 836880, a vascular endothelial growth factor/angiopoietin-2 inhibitor, administered once every 3 weeks or once weekly in patients with advanced solid tumors. ESMO Open. 7(5). 100576–100576.
11.
Ballot, Elise, Loïck Galland, Romain Boidot, et al.. (2022). Molecular intrinsic subtypes, genomic, and immune landscapes of BRCA-proficient but HRD-high ER-positive/HER2-negative early breast cancers. Breast Cancer Research. 24(1). 80–80.
12.
Piccart, Martine, Manuel Ruíz Borrego, H-T. Arkenau, et al.. (2021). 266P MEN1611, a PI3K inhibitor, combined with trastuzumab (T) ± fulvestrant (F) for HER2+/PIK3CA mutant (mut) advanced or metastatic (a/m) breast cancer (BC): Safety and efficacy results from the ongoing phase Ib study (B-PRECISE-01). Annals of Oncology. 32. S478–S479.
13.
Schmitt, Antonin, L. Uwer, Véronique Lorgis, et al.. (2021). 1707P A single G-CSF administration is enough to limit neutropenia in patients treated by eribulin. Annals of Oncology. 32. S1189–S1189.
14.
Fumet, Jean-David, Alice Hervieu, Audrey Hennequin, et al.. (2021). Phase I dose-escalation study of desynchronized irinotecan plus bevacizumab, oxaliplatin, 5-fluorouracil, and folinic acid (bFOLFIRINOX-3) administration in chemorefractory metastatic colorectal cancer patients.. Journal of Clinical Oncology. 39(15_suppl). e15573–e15573.
15.
Piccart, Martine, Manuel Ruíz Borrego, François P. Duhoux, et al.. (2020). 347P Results of the phase Ib dose escalation study of MEN1611, a PI3K inhibitor, combined with trastuzumab (T) ± fulvestrant (F) for HER2+/PIK3CA mutant (mut) advanced or metastatic (a/m) breast cancer (BC). Annals of Oncology. 31. S386–S386.
16.
Samalin, Emmanuelle, Anthony Turpin, Faïza Khemissa, et al.. (2019). Regorafenib combined with irinotecan as second-line treatment in patients with metastatic gastro-oesophageal adenocarcinomas: A randomized phase 2 trial (PRODIGE 58 – UCGI 35 – REGIRI). Annals of Oncology. 30. iv21–iv21.
17.
Orry, David, J. Fraisse, Julie Vincent, et al.. (2019). Safety and efficacy of a docetaxel-5FU-oxaliplatin regimen with or without trastuzumab in neoadjuvant treatment of localized gastric or gastroesophageal junction cancer: A retrospective study. World Journal of Gastrointestinal Oncology. 11(8). 634–641.
18.
Lagrange, Aurélie, et al.. (2019). Visceral osteopathic manipulative treatment reduces patient reported digestive toxicities induced by adjuvant chemotherapy in breast cancer: A randomized controlled clinical study. European Journal of Obstetrics & Gynecology and Reproductive Biology. 241. 49–55.
19.
Fumet, Jean David, Nicolás Isambert, Alice Hervieu, et al.. (2018). Phase Ib/II trial evaluating the safety, tolerability and immunological activity of durvalumab (MEDI4736) (anti-PD-L1) plus tremelimumab (anti-CTLA-4) combined with FOLFOX in patients with metastatic colorectal cancer. ESMO Open. 3(4). e000375–e000375.
20.
Hennequin, Audrey, Valentin Dérangère, Romain Boidot, et al.. (2015). Tumor infiltration by Tbet+ effector T cells and CD20+ B cells is associated with survival in gastric cancer patients. OncoImmunology. 5(2). e1054598–e1054598.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Andy Karabajakian Breakdown of academic impact, for papers by R. Houston Thompson Breakdown of academic impact, for papers by Giulia Mazzaschi Breakdown of academic impact, for papers by Virginia Palomar Coloma Breakdown of academic impact, for papers by Petros Fessas Breakdown of academic impact, for papers by Éléonore De Guillebon Breakdown of academic impact, for papers by Fanrong Zhang Breakdown of academic impact, for papers by Casilda Llácer Breakdown of academic impact, for papers by Muhammad Zubair Afzal Breakdown of academic impact, for papers by Rachel Marty Pyke